{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:12:40Z","timestamp":1788876760922,"version":"build-2803163510"},"reference-count":54,"publisher":"Sociedade Brasileira de Pneumologia e Tisiologia","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.pt-br"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Respir Res Clin Pract"],"abstract":"<jats:p>Objective: To describe clinical and epidemiological profile of patients with cystic fibrosis\n(CF) diagnosed outside neonatal screening programs at two referral centers in Rio de\nJaneiro, Brazil, and to assess the impact of diagnostic delay on disease severity at the\ntime of diagnosis. Methods: This cross-sectional study included 54 patients with a\nconfirmed diagnosis of CF evaluated at two CF referral centers in Rio de Janeiro between\n2019 and 2023. Data collected included age at diagnosis, neonatal screening history,\nclinical manifestations at diagnosis, previous misdiagnoses, microbiological findings,\npulmonary function, and nutritional status. Patients were stratified by age at diagnosis (&lt;\n5, 5-12, 13-17, and \u2265 18 years) and by pediatric versus adult diagnosis. Chi-square tests\nwere used for categorical comparisons. Results: Among the 54 patients, 59.3% were\nmale, and 98.1% were not identified by neonatal screening. Median age at diagnosis\nwas 11 years (IQR: 4.5-23.5). Diagnosis during adulthood occurred in 31.5% of patients.\nBronchiectasis was present in 88.2% of adults compared with 47.1% of pediatric cases\n(p = 0.0045). CF-related diabetes was exclusively observed in adults (41.2%; p &lt; 0.001).\nPrior misdiagnosis occurred in 45 patients (83.3%), most commonly asthma (24.1%),\ntuberculosis (11.1%), or idiopathic bronchiectasis (7.4%). At diagnosis, the median FEV1\nwas 62% of the predicted value among patients with available spirometry. Bacterial\nairway infection was detected in 81.5% of cases. Conclusions: Late CF diagnosis in\nRio de Janeiro occurred predominantly outside neonatal screening programs, with a\nmedian age at diagnosis of 11 years, reflecting substantial missed opportunities for early\nintervention. Diagnosis during adulthood is associated with higher rates of bronchiectasis\nand CF-related diabetes, highlighting the irreversible structural and metabolic burden\nassociated with diagnostic delay.<\/jats:p>","DOI":"10.36416\/1806-3756\/e20260136","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:03:13Z","timestamp":1788876193000},"page":"e20260136","source":"Crossref","is-referenced-by-count":0,"title":["Delayed diagnosis of cystic fibrosis: clinical burden and missed opportunities in a cohort from Rio de Janeiro, Brazil"],"prefix":"10.36416","author":[{"given":"Renata","family":"Wrobel Folescu Cohen","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jhswv08","id-type":"ROR","asserted-by":"publisher"}],"name":"Funda\u00e7\u00e3o Oswaldo Cruz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania","family":"Wrobel Folescu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jhswv08","id-type":"ROR","asserted-by":"publisher"}],"name":"Funda\u00e7\u00e3o Oswaldo Cruz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Yllel Rocha","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jhswv08","id-type":"ROR","asserted-by":"publisher"}],"name":"Funda\u00e7\u00e3o Oswaldo Cruz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Taulois","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jhswv08","id-type":"ROR","asserted-by":"publisher"}],"name":"Funda\u00e7\u00e3o Oswaldo Cruz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patr\u00edcia","family":"Fernandes Barreto Machado Costa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04jhswv08","id-type":"ROR","asserted-by":"publisher"}],"name":"Funda\u00e7\u00e3o Oswaldo Cruz"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raphael","family":"Freitas Jaber de Oliveira","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0198v2949","id-type":"ROR","asserted-by":"publisher"}],"name":"Universidade do Estado do Rio de Janeiro"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22288","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"ref0","doi-asserted-by":"crossref","unstructured":"1. Elborn JS. Cystic fibrosis. Lancet. 2016;388(10059):2519-2531.","DOI":"10.1016\/S0140-6736(16)00576-6"},{"key":"ref1","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0140-6736(16)00576-6","DOI":"10.1016\/S0140-6736(16)00576-6"},{"key":"ref2","unstructured":"2. Cutting GR. Cystic fibrosis genetics: from molecular understanding"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"to clinical application. Nat Rev Genet. 2015;16(1):45-56. https:\/\/doi.","DOI":"10.1038\/nrg3849"},{"key":"ref4","unstructured":"org\/10.1038\/nrg3849"},{"key":"ref5","unstructured":"3. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient"},{"key":"ref6","unstructured":"Registry 2022 Annual Data Report. Bethesda, MD: Cystic Fibrosis"},{"key":"ref7","unstructured":"Foundation; 2023. Available from: https:\/\/www.cff.org\/medicalprofessionals\/patient-registry"},{"key":"ref8","unstructured":"4. Southern KW, Munck A, Pollitt R, Travert G, Zanolla L, DankertRoelse J, et al. A survey of newborn screening for cystic fibrosis"},{"key":"ref9","unstructured":"in Europe. J Cyst Fibros. 2007;6(1):57-65. https:\/\/doi.org\/10.1016\/j."},{"key":"ref10","unstructured":"jcf.2006.05.008"},{"key":"ref11","unstructured":"5. Athanazio RA, Silva Filho LVRF, Vergara AA, Ribeiro AF, Riedi CA,"},{"key":"ref12","unstructured":"Procianoy EFA, et al. Brazilian guidelines for the diagnosis and"},{"key":"ref13","unstructured":"treatment of cystic fibrosis. J Bras Pneumol. 2017;43(3):219-245."},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1590\/s1806-37562017000000065","DOI":"10.1590\/s1806-37562017000000065"},{"key":"ref15","unstructured":"6. Grupo Brasileiro de Estudos de Fibrose C\u00edstica (GBEFC) [homepage"},{"key":"ref16","unstructured":"on the Internet]. Curitiba: GBEFC; c2022 [cited 2025 Jan 4]. Registro"},{"key":"ref17","unstructured":"Brasileiro de Fibrose C\u00edstica 2021. Available from: https:\/\/www."},{"key":"ref18","unstructured":"gbefc.org.br"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"7. Reis FJC, Damaceno N. Cystic fibrosis. J Pediatr (Rio J). 1998;74","DOI":"10.2223\/JPED.489"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Suppl 1:S76-94. https:\/\/doi.org\/10.2223\/JPED.489","DOI":"10.2223\/JPED.489"},{"key":"ref21","unstructured":"8. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med."},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"2005;352(19):1992-2001. https:\/\/doi.org\/10.1056\/NEJMra043184","DOI":"10.1056\/NEJMra043184"},{"key":"ref23","unstructured":"9. Scotet V, L\u2019Hostis C, Ferec C. The changing epidemiology of"},{"key":"ref24","unstructured":"cystic fibrosis: Incidence, survival and impact of the CFTR gene"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"discovery. Genes (Basel). 2020;11(6):589. https:\/\/doi.org\/10.3390\/","DOI":"10.3390\/genes11060589"},{"key":"ref26","unstructured":"genes11060589"},{"key":"ref27","unstructured":"10. European Cystic Fibrosis Society. ECFS Patient Registry Annual Data"},{"key":"ref28","unstructured":"Report 2020. Karup, Denmark: ECFS; 2022."},{"key":"ref29","unstructured":"11. Middleton PG, Mall MA, Drevinek P, Lands LC, McKone EF, Polineni"},{"key":"ref30","unstructured":"D, et al. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Single Phe508del Allele. N Engl J Med. 2019;381(19):1809-1819.","DOI":"10.1056\/NEJMoa1908639"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1056\/NEJMoa1908639","DOI":"10.1056\/NEJMoa1908639"},{"key":"ref33","unstructured":"12. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic"},{"key":"ref34","unstructured":"fibrosis-related diabetes: current trends in prevalence, incidence,"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"and mortality. Diabetes Care. 2009;32(9):1626-1631. https:\/\/doi.","DOI":"10.2337\/dc09-0586"},{"key":"ref36","unstructured":"org\/10.2337\/dc09-0586"},{"key":"ref37","unstructured":"13. Kerem E, Viviani L, Zolin A, MacNeill SJ, Hatziagorou E, Ellemunter H,"},{"key":"ref38","unstructured":"et al. Factors associated with FEV1 decline in cystic fibrosis: analysis"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"of the ECFS Patient Registry. Eur Respir J. 2014;43(1):125-133.","DOI":"10.1183\/09031936.00166412"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1183\/09031936.00166412","DOI":"10.1183\/09031936.00166412"},{"key":"ref41","unstructured":"14. Cystic Fibrosis Trust. Standards for the Clinical Care of Children and"},{"key":"ref42","unstructured":"Adults with Cystic Fibrosis in the UK. 3rd ed. London: CFT; 2020."},{"key":"ref43","unstructured":"15. Firmida MC, Lopes AJ. Epidemiologia e manifesta\u00e7\u00f5es cl\u00ednicas da"},{"key":"ref44","unstructured":"fibrose c\u00edstica. Rev Hosp Univ Pedro Ernesto. 2011;10(2):10-19."},{"key":"ref45","unstructured":"16. Heijerman HGM, McKone EF, Downey DG, Van Braeckel E,"},{"key":"ref46","unstructured":"Rowe SM, Tullis E, et al. Efficacy and safety of the elexacaftor"},{"key":"ref47","unstructured":"plus tezacaftor plus ivacaftor combination regimen in people with"},{"key":"ref48","unstructured":"cystic fibrosis homozygous for the F508del mutation. Lancet."},{"key":"ref49","unstructured":"2019;394(10212):1940-1948. https:\/\/doi.org\/10.1016\/S0140-"},{"key":"ref50","unstructured":"6736(19)32597-8"},{"key":"ref51","unstructured":"17. Castellani C, Duff AJA, Bell SC, Heijerman HGM, Munck A, Ratjen"},{"key":"ref52","unstructured":"F,et al. ECFS best practice guidelines: the 2018 revision. J Cyst"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Fibros. 2018;17(2):153-178. https:\/\/doi.org\/10.1016\/j.jcf.2018.02.006","DOI":"10.1177\/1534484318759399"}],"container-title":["Respiratory Research &amp; Clinical Practice"],"original-title":[],"link":[{"URL":"https:\/\/www.crossref.org\/categories\/similarity-check\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:03:27Z","timestamp":1788876207000},"score":1,"resource":{"primary":{"URL":"https:\/\/rrcpjournal.org\/wp-content\/uploads\/sites\/17\/2026\/08\/rrcp_2026-0136.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":54,"URL":"https:\/\/doi.org\/10.36416\/1806-3756\/e20260136","relation":{},"ISSN":["3086-3910"],"issn-type":[{"value":"3086-3910","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"2026-0136"}}